These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38606384)

  • 1. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product.
    Bernstein JS; Dhingra OP
    Ther Adv Urol; 2024; 16():17562872241241864. PubMed ID: 38606384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
    Swerdloff RS; Dudley RE
    Ther Adv Urol; 2020; 12():1756287220937232. PubMed ID: 32655691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism.
    DelConte A; Papangkorn K; Kim K; Bruno BJ; Chidambaram N; Khera M; Goldstein I; Kohler TS; Miner M; Dobs AS; Patel MV
    Andrology; 2022 May; 10(4):669-676. PubMed ID: 34994093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.
    White WB; Dobs A; Carson C; DelConte A; Khera M; Miner M; Shahid M; Kim K; Chidambaram N
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):630-637. PubMed ID: 34191621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men.
    White WB; Bernstein JS; Rittmaster R; Dhingra O
    J Clin Hypertens (Greenwich); 2021 Jul; 23(7):1420-1430. PubMed ID: 34114726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men.
    Yin A; Alfadhli E; Htun M; Dudley R; Faulkner S; Hull L; Leung A; Bross R; Longstreth J; Swerdloff R; Wang C
    J Androl; 2012; 33(6):1282-90. PubMed ID: 22790645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism.
    Miner M; Wang C; Kaminetsky J; Khera M; Goldstein I; Carson C; Chidambaram N; King S; Dobs A
    Andrology; 2024 Sep; ():. PubMed ID: 39252657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.
    Yin AY; Htun M; Swerdloff RS; Diaz-Arjonilla M; Dudley RE; Faulkner S; Bross R; Leung A; Baravarian S; Hull L; Longstreth JA; Kulback S; Flippo G; Wang C
    J Androl; 2012; 33(2):190-201. PubMed ID: 21474786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.
    Muram D; Ni X
    Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oral lipidic native testosterone formulation that is absorbed independent of food.
    Newell-Price J; Huatan H; Quirke J; Porter J; Daniel E; Mumdzic E; Voet B; Keevil B; Whitaker MJ; Ross RJ
    Eur J Endocrinol; 2021 Oct; 185(5):607-615. PubMed ID: 34379604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M; Cremers JF; Krallmann C; Kliesch S
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.